Literature DB >> 9031607

Association of natural killer cell immune recovery with a graft-versus-leukemia effect independent of graft-versus-host disease following allogeneic bone marrow transplantation.

Y Z Jiang1, A J Barrett, J M Goldman, D A Mavroudis.   

Abstract

There is good evidence that T lymphocytes play an important role in the graft-versus-leukemia (GVL) effect following allogeneic bone marrow transplantation (BMT) for hematologic malignancies. However, the role of natural killer (NK) cells in GVL is less clear. To further investigate a possible association of NK cells with GVL we studied 15 patients undergoing BMT for chronic myeloid leukemia (CML), correlating T-cell (CD4+ and CD8+) and NK-cell (CD16+ 56+) recovery with relapse and graft-versus-host disease (GVHD). Patients were studied on three occasions up to 9 months after BMT, for lymphocyte surface phenotype and for spontaneous and IL-2-stimulated (LAK cell) cytotoxic function. Circulating CD8+ and NK but not CD4+ cell numbers were significantly lower in five patients who relapsed compared with those remaining in remission after BMT (mean 0.03 vs 0.32 x 10(9)/l, p = 0.002 for CD8+ cells: mean 0.03 vs 0.11 x 10(9)/l, p = 0.002 for NK cells). There was no correlation of CD4+. CD8+, or NK cell numbers and development of grade-II or more acute GVHD. Spontaneous NK cytotoxic function rose to within the normal range in the first month after BMT. LAK function remained low during the study period. These results link NK cell recovery more closely with a GVL than with a GVH effect.

Entities:  

Mesh:

Year:  1997        PMID: 9031607     DOI: 10.1007/s002770050246

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  15 in total

Review 1.  Adoptive precursor cell therapy to enhance immune reconstitution after hematopoietic stem cell transplantation.

Authors:  J L Zakrzewski; A M Holland; M R M van den Brink
Journal:  J Mol Med (Berl)       Date:  2007-02-28       Impact factor: 4.599

2.  Absolute lymphocyte count on day 30 is a surrogate for robust hematopoietic recovery and strongly predicts outcome after T cell-depleted allogeneic stem cell transplantation.

Authors:  Bipin N Savani; Stephan Mielke; Katayoun Rezvani; Aldemar Montero; Agnes S Yong; Laura Wish; Jeannine Superata; Roger Kurlander; Anurag Singh; Richard Childs; A John Barrett
Journal:  Biol Blood Marrow Transplant       Date:  2007-08-24       Impact factor: 5.742

Review 3.  Strategies to enhance NK cell function for the treatment of tumors and infections.

Authors:  Jacquelyn Freund-Brown; Leilani Chirino; Taku Kambayashi
Journal:  Crit Rev Immunol       Date:  2018       Impact factor: 2.214

4.  Low blood lymphocyte count at 30 days post transplant predicts worse acute GVHD and survival but not relapse in a large retrospective cohort.

Authors:  Z Gul; E Van Meter; M Abidi; I Ditah; M Abdul-Hussein; A Deol; L Ayash; L G Lum; E K Waller; V Ratanatharathorn; J Uberti; Z Al-Kadhimi
Journal:  Bone Marrow Transplant       Date:  2015-01-19       Impact factor: 5.483

5.  Natural killer cells in acute myeloid leukemia patients: from phenotype to transcriptomic analysis.

Authors:  G Venton; Y Labiad; J Colle; A Fino; S Afridi; M Torres; S Monteuil; B Loriod; N Fernandez-Nunez; L Farnault; P Suchon; J C Mattei; P Rihet; A Bergon; C Nguyen; C Baier; R Costello
Journal:  Immunol Res       Date:  2016-12       Impact factor: 2.829

6.  The antileukemia effect of HLA-matched NK and NK-T cells in chronic myelogenous leukemia involves NKG2D-target-cell interactions.

Authors:  Giuseppe Sconocchia; Michelle Lau; Maurizio Provenzano; Katayoun Rezvani; Wachanan Wongsena; Hiroshi Fujiwara; Nancy Hensel; Jos Melenhorst; Jonming Li; Soldano Ferrone; A John Barrett
Journal:  Blood       Date:  2005-07-26       Impact factor: 22.113

7.  Factors associated with early molecular remission after T cell-depleted allogeneic stem cell transplantation for chronic myelogenous leukemia.

Authors:  Bipin N Savani; Katayoun Rezvani; Stephan Mielke; Aldemar Montero; Roger Kurlander; Charles S Carter; Susan Leitman; Elizabeth J Read; Richard Childs; A John Barrett
Journal:  Blood       Date:  2005-08-30       Impact factor: 22.113

8.  ICSBP-mediated immune protection against BCR-ABL-induced leukemia requires the CCL6 and CCL9 chemokines.

Authors:  Valentina Nardi; Olaia Naveiras; Mohammad Azam; George Q Daley
Journal:  Blood       Date:  2009-01-26       Impact factor: 22.113

9.  Response and toxicity of donor lymphocyte infusions following T-cell depleted non-myeloablative allogeneic hematopoietic SCT from 3-6/6 HLA matched donors.

Authors:  D A Rizzieri; P Dev; G D Long; C Gasparetto; K M Sullivan; Ml Horwitz; J Chute; N J Chao
Journal:  Bone Marrow Transplant       Date:  2008-10-13       Impact factor: 5.483

10.  Impact of graft cell dose on transplant outcomes following unrelated donor allogeneic peripheral blood stem cell transplantation: higher CD34+ cell doses are associated with decreased relapse rates.

Authors:  Ryotaro Nakamura; Nademanee Auayporn; David D Smith; Joycelynne Palmer; Joel Y Sun; Jeffrey Schriber; Vinod Pullarkat; Pablo Parker; Roberto Rodriguez; Anthony Stein; Joseph Rosenthal; Shirong Wang; Chatchada Karanas; Karl Gaal; David Senitzer; Stephen J Forman
Journal:  Biol Blood Marrow Transplant       Date:  2008-04       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.